GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MedCap AB (OSTO:MCAP) » Definitions » Peter Lynch Fair Value

MedCap AB (OSTO:MCAP) Peter Lynch Fair Value : kr337.50 (As of May. 28, 2025)


View and export this data going back to 2004. Start your Free Trial

What is MedCap AB Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, MedCap AB's PEG is 1. MedCap AB's 5-Year TTM EBITDA Growth Rate is 25. MedCap AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was kr13.50. Therefore, the Peter Lynch Fair Value for today is kr337.50.

As of today (2025-05-28), MedCap AB's share price is kr437.00. MedCap AB's Peter Lynch fair value is kr337.50. Therefore, MedCap AB's Price to Peter Lynch Fair Value Ratio for today is 1.29.


The historical rank and industry rank for MedCap AB's Peter Lynch Fair Value or its related term are showing as below:

OSTO:MCAP' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.96   Med: 1.45   Max: 12.83
Current: 1.29


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of MedCap AB was 12.83. The lowest was 0.96. And the median was 1.45.


OSTO:MCAP's Price-to-Peter-Lynch-Fair-Value is ranked better than
59.88% of 172 companies
in the Medical Devices & Instruments industry
Industry Median: 1.61 vs OSTO:MCAP: 1.29

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


MedCap AB Peter Lynch Fair Value Historical Data

The historical data trend for MedCap AB's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedCap AB Peter Lynch Fair Value Chart

MedCap AB Annual Data
Trend Apr15 Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 107.50 162.48 197.50 292.50 347.50

MedCap AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 345.00 360.00 382.50 347.50 337.50

Competitive Comparison of MedCap AB's Peter Lynch Fair Value

For the Medical Devices subindustry, MedCap AB's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where MedCap AB's Price-to-Peter-Lynch-Fair-Value falls into.


;
;

MedCap AB Peter Lynch Fair Value Calculation

MedCap AB's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *13.5
=337.50

MedCap AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr13.50.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


MedCap AB  (OSTO:MCAP) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

MedCap AB's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=437.00/337.50
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedCap AB Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of MedCap AB's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


MedCap AB Business Description

Traded in Other Exchanges
N/A
Address
Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.

MedCap AB Headlines

From GuruFocus

MCAP Inc. Reports First Quarter 2022 EPS of $0.15 Per Share

By PRNewswire PRNewswire 06-18-2022

MCAP Inc. Expands Equities Division with Senior Hire

By PRNewswire PRNewswire 07-07-2022

MCAP Inc. Reports First Quarter 2022 EPS of $0.15 Per Share

By PRNewswire PRNewswire 06-28-2022

MCAP Inc. Reports Fourth Quarter 2022 EPS of $0.17 Per Share

By PRNewswire PRNewswire 02-16-2023

MCAP Inc. Reports First Quarter 2022 EPS of $0.15 Per Share

By PRNewswire PRNewswire 05-09-2022

MetaCap Inc. Announces New Board Members

By PRNewswire PRNewswire 02-03-2022

MCAP Inc. Announces $0.05 Dividend Per Share

By PRNewswire 03-13-2024

MCAP Inc. Expands ETF Division and Announces Senior Hire

By PRNewswire PRNewswire 10-19-2022